BioNTech Stock Forecast
NASDAQ: BNTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
BNTX analyst consensus
Consensus (20 analysts)
buy
Avg. price target
$115.79+25.78%
- Strong buy 1
- Buy 13
- Hold 5
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 20 Wall Street analysts covering BioNTech (2026-10-07), 14 rate the stock a buy or strong buy, 5 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $115.79, with a high estimate of $139.32 and a low estimate of $73.03. The average target implies upside of 25.8% from the current price of $92.06.
The spread between the highest and lowest targets is 90.8%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for BNTX.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 5% |
| Buy | 13 | 65% |
| Hold | 5 | 25% |
| Sell | 0 | 0% |
| Strong sell | 1 | 5% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $73.03 | -20.67% |
| Average target | $115.79 | +25.78% |
| High target | $139.32 | +51.34% |